Pharmacotherapy of Ulcerative Colitis: What Role for Mesalamine?
نویسندگان
چکیده
Goals of treatment for ulcerative colitis (UC) include inducing remission, reducing symptom burden, and maintaining disease quiescence. Mesalamine is indicated for the management of mild to moderate ulcerative colitis. There are various dosages, formulations, and mechanisms of delivery that are efficacious and currently utilized in the treatment of UC. Mesalamine therapy (formulation and dosage) should be tailored on an individual basis depending on extent and severity of disease. Newer delivery systems can consolidate dosing regimens and possibly increase compliance. In general, mesalamine has been well tolerated with minimal side effects. In addition, mesalamine has been postulated to play a role in the chemoprophylaxis of colon cancer in patients with ulcerative colitis.
منابع مشابه
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the fi...
متن کاملUpdate on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current understanding of the mechanism of action of 5-ASA in inflammatory bowel disease. We evaluate evi...
متن کاملPatient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
Mesalamine and its derivatives are effective and well-tolerated therapies for ulcerative colitis. However, patient adherence to traditional mesalamine-based therapy is poor, and is often limited by heavy pill burdens and frequent dosing intervals. This can lead to ineffective disease control, impaired quality of life, and preventable morbidity and mortality. Previous studies have suggested that...
متن کاملMesalamine treatment mimicking relapse in a child with ulcerative colitis.
BACKGROUND There are reports on mesalamine-induced bloody diarrhea mimicking ulcerative colitis (UC) relapse, mostly in adults. METHODS Herein we present a case of a child with UC who developed relapse of hemorrhagic colitis related to mesalamine. RESULTS A 10-year-old girl developed severe symptoms mimicking UC relapse 3 weeks after introduction of mesalamine therapy. After mesalamine was ...
متن کاملHuman Pharmacokinetics and Metabolism Absorption. PENTASA is an ethylcellulose-coated, controlled-release formulation of mesalamine designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. Based on urinary excretion data, 20% to 30% of the mesalamine in PENTASA
CLINICAL PHARMACOLOGY Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component is therapeutically active in ulcerative colitis. The usual oral dose of sulfasalazine for active ulcerative colitis in adults is 2 to 4 g per day in divided doses. Four grams of sulfasalazine provide 1.6 g of free mesalamine to...
متن کامل